Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00191971
Status:
COMPLETED
Last Update Posted:
2007-11-06
First Post:
2005-09-12
Brief Title:
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium TCC After CDDP Regimen
Sponsor:
Organization:
Eli Lilly and Company
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
40
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: